Page 263

Catalogue_WEB_WoP_Jun16

Pricing and Online Ordering at www.alphalabs.co.uk Faecal Testing Automated Quantitative Faecal Immunochemical Testing (qFIT) Automated Quantitative Faecal Immunochemical Testing (qFIT) Guaiac-based Faecal Occult Blood Tests (gFOBT) have been used for many years in both diagnosis of the symptomatic and screening of the asymptomatic. However, it is now widely recognised that Quantitative Faecal Immunochemical Testing (qFIT) provides greater sensitivity and specificity for identifying haemoglobin in faeces. This has resulted in many laboratories eliminating gFOBT, consequently creating an increase in referrals for colonoscopy in those presenting with lower abdominal symptoms, since these overlap considerably in serious colorectal disease and benign and functional bowel disorders. Colonoscopy resources are under considerable pressure and, despite increasing referrals, disease detection remains low, only about a third of symptomatic patients having an abnormality detected. In recent years, some countries have replaced the traditional gFOBT strategy for screening with FIT (Faecal Immunochemical Tests for haemoglobin) since they provide better analytical sensitivity and specificity for human haemoglobin and are superior in detection of adenomatous polyps as well as colorectal cancers (CRC). Currently, there are many studies, published and in progress, that examine the usefulness of measuring faecal haemoglobin quantitatively in those presenting with symptoms. If useful in this setting, FIT could potentially reduce the burden of colonoscopy in a similar way to calprotectin testing, provided FIT were adopted as a routine test for the symptomatic. A recently accepted article1,concluded that FIT is highly accurate for the detection of CRC in symptomatic patients and was more so than the NICE (National Institute for Health and Care Excellence) and SIGN (Scottish Intercollegiate Guidelines Network) referral criteria. This work demonstrated that, when FIT with a 20 μg Hb/g faeces cut-off concentration was used instead of the NICE referral criteria, 19.6% fewer colonoscopies would have been needed to detect 42% additional CRC. Alpha Laboratories currently supplies the four UK Bowel Screening Programmes with both gFOBT and FIT. Keeping pace with advancing technologies and requirements in this area, we are pleased to introduce a new quantitative FIT assay performed on an automated immunoturbidimetric analytical system. See pages 262-263 for full details about the HM-JACKarc system. Reference 1. Cubiella J, et al. Diagnostic accuracy of faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria. Colorectal Dis. 2014 Jan 24. doi: 10.1111/codi.12569 n email order sales@alphalabs.co.uk n freefax order 0800 614249 261


Catalogue_WEB_WoP_Jun16
To see the actual publication please follow the link above